Press Releases

Press Releases

Samsung Biologics and Bristol-Myers Squibb announce Biopharmaceutical Manufacturing Relationship

 

Samsung Biologics and Bristol-Myers Squibb announce Biopharmaceutical Manufacturing Relationship
 

Seoul(Korea) July 29th, 2013 ? Samsung Biologics and Bristol-Myers Squibb Company announced the companies have entered into a 10-year agreement under which Samsung Biologics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.

Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013.

 

For more informations, please enter the following address.

 

Samsung Biologics and Bristol-Myers Squibb announce Biopharmaceutical Manufacturing Relationship
 

Seoul(Korea) July 29th, 2013 – Samsung Biologics and Bristol-Myers Squibb Company announced the companies have entered into a 10-year agreement under which Samsung Biologics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.

Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013.

 

For more informations, please enter the following address.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION